Search results
Results from the WOW.Com Content Network
Denervation processes are strongly associated with the symptoms experienced in post-polio syndrome. Individuals with post-polio syndrome undergo a continuous cycle of denervation and reinnervation that occurs after acute poliomyelitis. Over time, this cycle leads to an increase in the size of motor units in skeletal muscle fibers. Eventually ...
The United States Food and Drugs Administration is warning pet owners about a common medication given to pets to treat arthritis. The F.D.A. now says that the drug Librela may be associated with ...
The disease is gradually progressive. Treatment is possible with corticosteroids, but the prognosis is poor. Sensory neuropathies are inherited conditions in dogs and cause an inability to feel pain and a loss of proprioception. Self-mutilation is often seen. No treatment has been found, and the prognosis is poor in severe cases.
The dog medication Librela is likely sickening and killing dogs, the FDA warned. Ermolaev Alexandr – stock.adobe.com More than 3,600 cases of Librela harming dogs have been reported to the FDA.
A dog with degenerative myelopathy often stands with its legs close together and may not correct an unusual foot position due to a lack of conscious proprioception. Canine degenerative myelopathy, also known as chronic degenerative radiculomyelopathy, is an incurable, progressive disease of the canine spinal cord that is similar in many ways to amyotrophic lateral sclerosis (ALS).
Diabetes is the foremost cause in America today for neuropathic joint disease, [5] and the foot is the most affected region. In those with foot deformity, approximately 60% are in the tarsometatarsal joints (medial joints affected more than lateral), 30% metatarsophalangeal joints, and 10% have ankle disease. Over half of diabetic patients with ...
[3] [11] Dogs suffering systemic manifestations of the disorder often have poorer prognoses. Systemic manifestations include fever, multiple body organ inflammation, nasal (nose) and ocular (eye) discharge, diarrhea, hyperkeratosis of the foot pads, pneumonia , and tooth enamel hypoplasia (many of these symptoms overlap with symptoms of CDV).
Maropitant (INN; [3] brand name: Cerenia, used as maropitant citrate , is a neurokinin-1 (NK 1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [4] [5] and in 2012, for cats. [6]